Publication:
The global burden of chronic urticaria for the patient and society*

Issued Date

2021-02-01

Resource Type

Article

ISSN

13652133
00070963

DOI

10.1111/bjd.19561

Other identifier(s)

2-s2.0-85096658120

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

British Journal of Dermatology. Vol.184, No.2 (2021), 226-236

Suggested Citation

M. Gonçalo, A. Gimenéz-Arnau, M. Al-Ahmad, M. Ben-Shoshan, J. A. Bernstein, L. F. Ensina, D. Fomina, C. A. Galvàn, K. Godse, C. Grattan, M. Hide, C. H. Katelaris, M. Khoshkhui, E. Kocatürk, K. Kulthanan, I. Medina, I. Nasr, J. Peter, P. Staubach, L. Wang, K. Weller, M. Maurer The global burden of chronic urticaria for the patient and society*. British Journal of Dermatology. Vol.184, No.2 (2021), 226-236. doi:10.1111/bjd.19561 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78500

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

The global burden of chronic urticaria for the patient and society*

Author(s)

M. Gonçalo
 A. Gimenéz-Arnau
 M. Al-Ahmad
 M. Ben-Shoshan
 J. A. Bernstein
 L. F. Ensina
 D. Fomina
 C. A. Galvàn
 K. Godse
 C. Grattan
 M. Hide
 C. H. Katelaris
 M. Khoshkhui
 E. Kocatürk
 K. Kulthanan
 I. Medina
 I. Nasr
 J. Peter
 P. Staubach
 L. Wang
 K. Weller
 M. Maurer

Other Contributor(s)

Hiroshima University Graduate School of Biomedical and Health Sciences
 University of Cape Town Lung Institute
 Royal Hospital
 Instituto Nacional de Salud del Nino, Lima
 Pirogov Russian National Research Medical University (RNRMU)
 Kuwait University
 Universidade de Coimbra, Faculdade de Medicina
 Centre Universitaire de Santé McGill, Hôpital de Montreal Pour Enfants
 Charité – Universitätsmedizin Berlin
 Universitätsmedizin Mainz
 Sun Yat-Sen University
 Western Sydney University
 University of Cincinnati College of Medicine
 Universidade Federal de São Paulo
 Faculty of Medicine Siriraj Hospital, Mahidol University
 Sechenov First Moscow State Medical University
 Guy's Hospital
 Koç Üniversitesi
 Mashhad University of Medical Sciences
 Institut Municipal d'Investigacio Medica
 Centro Médico Vitae

Abstract

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1-antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1-antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients’ quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients’ performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/78500

Collections

Scopus 2021